Background We conducted a phase II trial of erlotinib in patients with advanced non-small-
cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and …

Background and objective Targeted therapy in non-small cell lung cancer (NSCLC) had
become a research hotspot. Both of gefitinib and erlotinib had already been recommended …

Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …

Introduction Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the
preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR …

Background Patients with EGFR-mutated non-small-cell lung cancer benefit from EGFR
tyrosine kinase inhibitors (TKIs) like erlotinib. However, the efficacy may be impaired by …

7522 Background: When EGFR compound mutants (exon 19 deletions or L858R
plusT790M) are present at the time of clinical resistance to erlotinib, patients attain longer …

7020 Background: The EGFR TK inhibitor erlotinib is a standard treatment in previously
treated NSCLC p. Recently, EGFR gene mutations have been reported to be a predictor of …

8080 Background: Erlotinib and gefitinib have been shown to have similar activity for EGFR
mutation-positive (EGFRm+) NSCLC. Since the steady-state plasma trough concentration of …

Erlotinib is an orally administered small-molecule inhibitor of EGF receptor (EGFR) tyrosine
kinase that is approved for the treatment of non-small-cell lung cancer (NSCLC) and …

9007 Background: In JO25567 (Clinical trials registry number. JapicCTI-111390), EB
significantly prolonged progression-free survival (PFS) in patients with NSCLC with …